Array BioPharma
Array BioPharma is a Boulder-based biopharmaceutical company specializing in BRAF and MEK kinase inhibitors for oncology, now operating as a wholly-owned Pfizer subsidiary commercializing BRAFTOVI and Mektovi for BRAF-driven cancers including metastatic colorectal cancer.
- Company typePrivate
- Founded1998
- HeadquartersBoulder, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Array BioPharma does
Array BioPharma is a Boulder, Colorado-based biopharmaceutical company founded in 1998 that develops and commercializes targeted small-molecule oncology drugs, with a domain specialization in BRAF and MEK kinase inhibitors. Following its acquisition by Pfizer, it operates as a wholly-owned subsidiary within one of the world's premier biopharmaceutical companies, with its oncology assets (BRAFTOVI/encorafenib and Mektovi/binimetinib) commercialized via Pfizer's global pharmaceutical distribution infrastructure.
The company's core products address BRAF-driven cancers. BRAFTOVI (encorafenib), a BRAF kinase inhibitor, was approved by the FDA in combination with cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC), supported by Pfizer's Phase 3 BREAKWATER trial demonstrating improved objective response rate, progression-free survival, and overall survival. In January 2026, the FDA approved Guardant Health's Guardant360 CDx as a companion diagnostic to identify eligible patients via non-invasive liquid biopsy. Mektovi (binimetinib), a MEK inhibitor, is co-administered with BRAFTOVI in combination regimens for BRAF-mutant solid tumors including melanoma. The company's customer base spans oncologists, oncology centers, hospitals, and specialty pharmacies.
Array BioPharma's revenue model is pharmaceutical drug sales of proprietary oncology therapeutics, with revenue now flowing entirely through Pfizer's consolidated commercial operations following the acquisition. Pricing is not publicly disclosed in the source material. The company employs 101-250 people, was previously listed on NASDAQ under ticker ARRY before being delisted upon acquisition, and has a prior leadership team including CEO Robert Conway and COO David L. Snitman.
Array BioPharma firmographics
Firmographics- Name
- Array BioPharma
- Legal name
- Array BioPharma
- Website
- https://arraybiopharma.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Array BioPharma is a Boulder-based biopharmaceutical company specializing in BRAF and MEK kinase inhibitors for oncology, now operating as a wholly-owned Pfizer subsidiary commercializing BRAFTOVI and Mektovi for BRAF-driven cancers including metastatic colorectal cancer.
- Ownership category
- akta.pro rank
Array BioPharma industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
Keywords
Where Array BioPharma is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Markets served
Array BioPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Pharmaceutical drug sales: Revenue from commercialization of proprietary oncology drugs such as BRAFTOVI (encorafenib) and Mektovi (binimetinib). Following Pfizer's acquisition of Array BioPharma, drug sale revenue flows through Pfizer's pharmaceutical commercial operations.
Go-to-market motion1 record
Distribution channels2 records
Array BioPharma product offering
Product offeringCore offering
Array BioPharma is a biopharmaceutical company that develops and commercializes targeted small molecule oncology drugs, most notably BRAFTOVI (encorafenib), a BRAF kinase inhibitor, and Mektovi (binimetinib), a MEK inhibitor, used as combination regimens for BRAF V600E-mutant metastatic colorectal cancer and other BRAF-driven cancers. Following its acquisition by Pfizer, the company's assets are developed and commercialized within Pfizer's oncology franchise, including the Phase 3 BREAKWATER trial supporting BRAFTOVI's expanded indication.
Differentiator
Problem solved
Functional benefit
Brands
- BRAFTOVI: BRAFTOVI (encorafenib) is a BRAF inhibitor developed by Array BioPharma, indicated (in combination with cetuximab and chemotherapy) for BRAF V600E-mutant metastatic colorectal cancer and previously approved for melanoma.
- Mektovi
Products and services
- BRAFTOVI (encorafenib) BRAFTOVI (encorafenib) is a BRAF kinase inhibitor indicated in combination with cetuximab and chemotherapy for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC); previously approved for melanoma. It is a targeted oncology therapy commercialized within Pfizer's oncology franchise post-acquisition.
- Mektovi (binimetinib) Mektovi (binimetinib) is a MEK inhibitor co-developed by Array BioPharma and used in combination regimens alongside BRAFTOVI for the treatment of BRAF-mutant cancers, including melanoma.
Quantifiable outcome
- Improved objective response rate, progression-free survival, and overall survival with encorafenib-based combination in BRAF V600E-mutant mCRC (Phase 3 BREAKWATER trial)
- +1 more outcomes
Companies that use Array BioPharma
Customer profileSegments2 records
Ideal customer profiles1 record
Array BioPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Array BioPharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Guardant HealthcoreGuardant Health's Guardant360 CDx was FDA-approved as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for Array BioPharma's BRAFTOVI in combination with cetuximab and chemotherapy. This represents Guardant360 CDx's 25th companion diagnostic indication across multiple tumor types, enabling non-invasive liquid biopsy-based patient identification.
- PfizerflagshipPfizer acquired Array BioPharma and now leads the commercialization and clinical development of Array BioPharma's oncology assets. Pfizer's Phase 3 BREAKWATER trial supported the FDA approval of BRAFTOVI in BRAF V600E-mutant mCRC. The integration places Array BioPharma's pipeline within one of the world's premier biopharmaceutical companies.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Array BioPharma competitors and assessment
Company assessmentDirect peers
- Roche: Roche markets vemurafenib (Zelboraf), the first FDA-approved BRAF inhibitor, and cobimetinib (Cotellic), a MEK inhibitor, forming a direct competitive combination therapy to Array BioPharma's BRAFTOVI/Mektovi in BRAF-mutant cancers.
- Novartis: Novartis markets dabrafenib (Tafinlar) and trametinib (Mekinist), a direct BRAF/MEK inhibitor combination that competes directly with Array BioPharma's BRAFTOVI/Mektovi regimen in BRAF-mutant melanoma and other BRAF-driven cancers.
- Genentech: Genentech (a Roche subsidiary) developed vemurafenib and cobimetinib, making it a direct competitor to Array BioPharma in the BRAF/MEK inhibitor space for BRAF-mutant cancers.
Broad incumbents
- Pfizer: Pfizer is Array BioPharma's parent company and a premier biopharmaceutical company with a broad oncology portfolio. Pfizer acquired Array BioPharma and now leads commercialization of Array's drugs, making it both the parent and a broad incumbent in the oncology space.
- Merck & Co. Merck is a premier biopharmaceutical company with a leading oncology franchise (Keytruda). Its scale, commercial reach, and oncology pipeline make it a broad incumbent in the oncology drug market.
- Amgen: Amgen is a large biopharmaceutical company with an oncology portfolio including targeted therapies. Its scale and commercial infrastructure make it a broad incumbent in oncology drug development and commercialization.
- AstraZeneca: AstraZeneca has a significant oncology portfolio including targeted therapies across multiple cancer types. Its scale and oncology pipeline breadth position it as a broad incumbent competitor in the targeted oncology space.
- Bristol-Myers Squibb: Bristol-Myers Squibb is a major oncology biopharmaceutical company with targeted therapy offerings including Opdivo and Yervoy. It competes broadly in the oncology space where Array BioPharma's BRAFTOVI operates.
Others
- Guardant Health: Guardant Health is Array BioPharma's companion diagnostic partner, with its Guardant360 CDx FDA-approved to identify BRAF V600E-mutant mCRC patients eligible for BRAFTOVI. As a precision oncology diagnostics company, it is an enabling partner in Array BioPharma's treatment ecosystem.
Emerging players
- BeiGene: BeiGene is an emerging oncology biopharmaceutical company developing targeted therapies including BTK inhibitors and immuno-oncology agents. It represents an emerging player in the oncology space with growing global commercialization capabilities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights5 records
Customer concentration
Array BioPharma social profiles
Digital presenceArray BioPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Array BioPharma leadership team
Management profileNumber of profiles
Profiles3 records
Array BioPharma funding detail
Funding detailFunding overview
Funding rounds6 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Array BioPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Array BioPharma
What does Array BioPharma do?
Array BioPharma is a biopharmaceutical company that develops and commercializes targeted small molecule oncology drugs, most notably BRAFTOVI (encorafenib), a BRAF kinase inhibitor, and Mektovi (binimetinib), a MEK inhibitor, used as combination regimens for BRAF V600E-mutant metastatic colorectal cancer and other BRAF-driven cancers. Following its acquisition by Pfizer, the company's assets are developed and commercialized within Pfizer's oncology franchise, including the Phase 3 BREAKWATER trial supporting BRAFTOVI's expanded indication.
Is Array BioPharma a public or private company?
Array BioPharma is a private company. It is classified as corporate owned and is currently acquired.
When was Array BioPharma founded?
Array BioPharma was founded in 1998. It employs 101 to 250 people.
Where is Array BioPharma based?
Array BioPharma is headquartered in Boulder, United States, in the North America region.
How does Array BioPharma make money?
One revenue line is on record: pharmaceutical drug sales.
Who are Array BioPharma's main competitors?
Direct peers on record are Roche, Novartis and Genentech. Broad incumbents are Pfizer, Merck & Co., Amgen, AstraZeneca and Bristol-Myers Squibb. Guardant Health is listed as an others. BeiGene is listed as an emerging player.
Does Array BioPharma have an API?
No public API is recorded for Array BioPharma.
What industry is Array BioPharma in?
Array BioPharma's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.